Inhaled muscarinic antagonists for COPD-does an anti-inflammatory mechanism really play a role?

Current Opinion in Pharmacology

Volumn 9, Issue 3, 2009, Pages 250-255

  Trevethick, Michael ^a   Clarke, Nicholas ^a   Strawbridge, Matthew ^a   Yeadon, Michael ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M3 RECEPTOR; OXYBUTYNIN; TIOTROPIUM BROMIDE;

ACETYLCHOLINE RELEASE; ANTIINFLAMMATORY ACTIVITY; BRONCHODILATING ACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG EFFICACY; DYSPNEA; EXERCISE TOLERANCE; HUMAN; HYPERINFLATION; LUNG BLOOD VESSEL; NERVE STIMULATION; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY AIRFLOW; REVIEW; SMOOTH MUSCLE; VAGUS NERVE; VIRUS INHIBITION;

ADMINISTRATION, INHALATION; ANIMALS; ANTI-INFLAMMATORY AGENTS; BRONCHODILATOR AGENTS; HUMANS; INFLAMMATION; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SCOPOLAMINE DERIVATIVES; VIRUS DISEASES;

EID: 65749085854     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2009.02.003     Document Type: Review

References (42)

1. Varkey J.B., and Varkey B. Viral infections in patients with chronic obstructive pulmonary disease. Curr Opin Pulm Med 14 (2008) 89-94
2. Sethi S., and Murphy T.F. Infection in the pathogenesis and course of chronic obstructive pulmonary diseases. N Eng J Med 359 (2008) 2355-2365
3. Donaldson G.C., and Wedzicha J.A. COPD exacerbations. Thorax 61 (2006) 164-168
4. Gwilt C.R., Donnelly L.E., and Rogers D.F. The non-neuronal cholinergic system in the airways: an unappreciated regulatory role in pulmonary inflammation. Pharmacol Ther 115 (2007) 208-222
5. Chen A.M., Bollmeier S.G., and Finnegan P.M. Long acting bronchodilator therapy for the treatments of chronic obstructive pulmonary disease. Ann Pharmacother 42 (2008) 1832-1842
6. Gosens R., Zaagsma J., Meurs H., and Halayko A. Muscarinic receptor signalling in the pathophysiology of asthma and COPD. Respir Res 7 (2006) 1-15. Excellent review documenting the role of neuronal and non-neuronal acetylycholine, muscarinic receptors and signalling pathways in pathogenesis of asthma and COPD.
7. Kummer W., and Lips K.S. Non-neuronal acetylcholine release and its contribution to COPD pathology. Drug Disc Today 3 (2006) 47-52
8. 4 and that this was inhibited by tiotropium.
9. Buhling F., Lieder N., Kuhlmann U.C., Waldburg N., and Welte T. Tiotropium suppresses acetylcholine-induced release of chemotactic mediators in vitro. Respir Med 101 (2007) 2386-2394
10. Profita M., Bonanno A., Siena L., Ferraro M., Montalbano A.M., Pompeo F., Riccobono L., Poeper M.P., and Gjomarkaj M. Acetylcholine mediates release of IL-8 in human bronchial epithelial cells by a NFκB/ERK dependent mechanism. Eur J Pharmacol 582 (2008) 145-153
11. Haag S., Matthiesen S., Juergens U.R., and Racke K. Muscarinic receptors mediated stimulation of collagen synthesis in human lung fibroblasts. Eur Respir J 32 (2008) 555-562
12. 3-receptors mediate cholinergic synergism of mitogenesis in airway smooth muscle. Am J Respir Cell Mol Biol 28 (2003) 257-262
13. Wilkinson T.M.A., Patel I.S., Wilks M., Donaldson G.C., and Wedzicha J.A. Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 167 (2003) 1090-1095
14. Wilkinson T.M.A., Donaldson G.C., Johnston S.L., Openshaw P.J.M., and Wedzicha J.A. Respiratory syncytial virus, airway inflammation and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 173 (2006) 871-876
15. Wedzicha J.A., Calverley P.M.A., Seemerungal T.A., Hagan G., Ansari Z., and Stockley R. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 177 (2008) 19-26
16. Barnes N.C., Qui Y.-S., Pavord I.D., Parker D., Davis P.A., Zhu J., Johnson M., Thomson N.C., and Jeffery P.K. Anti-inflammatory effects of salmeterol/fluticasone proprionate in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 173 (2006) 736-743. Clinical paper documenting the anti-inflammatory effects of salmeterol/fluticasone in COPD in lung biopsies.
17. Tashkin D.P., Celli B., Senn S., Burkhart D., Kesten S., Menjoge S., and Decramer M. A 4 year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359 (2008) 1543-1554
18. Powrie D.J., Wilkinson T.M.A., Donaldson G.C., Jones P., Scrine K., Viel K., Kesten S., and Wedzicha J.A. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur Respir J 30 (2007) 472-478. Paper demonstrating that tiotropium did not exhibit anti-inflammatory effects in sputum and serum from patients with COPD.
19. Saito S., and Okazawa M. Eosinophilic leukocyte accumulation during vagal induced bronchoconstriction. Am J Respir Cit Care Med 156 (1997) 1614-1620
20. Cui Y.-Y., Zhu L., Advenier C., Chen H.-Z., and Devillier P. Muscarinic receptor involved in airway vascular leakage induced by experimental gastro-oesophageal reflux. Life Sci 82 (2008) 949-955
21. McQueen D.S., Donaldson K., Bond S.M., McNeilly J.D., Newman S., Barton N.J., and Duffin R. Bilateral vagotomy or atropine pre-treatment reduces experimental diesel soot induced lung inflammation. Toxicol Appl Pharmacol 219 (2007) 62-71
22. Bos I.S.T., Gosens R., Zuidhof A.B., Schaafsma D., Halayko A.J., Meurs H., and Zaagsma J. Inhibition of allergen induced airway remodelling by tiotropium and budesonide: a comparison. Eur Respir J 30 (2007) 653-671
23. Gosens R., Bos S.T., Zaagsma J., and Meurs H. Protective effects of tiotropium bromide in the progression of airway smooth muscle remodelling. Am J Respir Cit Care Med 171 (2005) 1096-1102
24. Casaburi R., and Porszasz J. Reduction of hyperinflation by pharmacological and other interventions. Proc Am Thorac Soc 3 (2006) 185-189
25. Ferguson G.T. Why does the lung hyperinflate?. Proc Am Thorac Soc 3 (2006) 176-179
26. Cooper C.B. The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function. Am J Med 119 (2006) S21-S31. Review article suggesting that lung hyperinflation is an important factor in disease pathology of COPD and that its measurement is crucial in patient assessment.
27. Belmonte K.E. Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc Am Thorac Soc 2 (2005) 297-304
28. O'Donnell D.E., Fluge T., Gerken F., Hamilton A., Webb K., Aguilaniu B., Make B., and Magnussen H. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 23 (2004) 832-840
29. Cazzola M., Hanania N.A., Jones P.W., Mahker D.A., Make B., Ohar J., and Rennard S. It's about time-directing our attention toward modifying the course of COPD. J Respir Med 102 Suppl. 1 (2008) S37-S48
30. Cooper C.B., and Dransfield M. Primary care of the patients with chronic obstructive pulmonary disease-Part 4: understanding the clinical manifestations of a progressive disease. Am J Med 121 (2008) S33-S45
31. Travers J., Laveneziana P., Webb K.A., Kesten S., and O'Donnell. Effect of tiotropium bromide on the cardiovascular response to exercise in COPD. Respir Med 101 (2007) 2017-2024
32. Racke K., Juergens U.R., and Matthiesen S. Control by cholinergic mechanisms. Eur J Pharmacol 533 (2006) 57-68
33. Yang Q., Underwood M.J., Hsin H., Liu X.C., and He G.W. Dysfunction of pulmonary vascular endothelium in chronic obstructive pulmonary disease: basic considerations for future drug development. Curr Drug Metab 9 (2008) 661-667
34. Tamagawa E., Bai N., Morimoto K., Gray C., Mui T., Yatera K., Zhang X., Xing L., Laher I., Sin D.D., et al. Particulate matter exposure induces persistent lung inflammation and endothelial dysfunction. Am J Physiol Lung Cell Mol Physiol 295 (2008) L79-L85
35. Sin D.D. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 107 (2003) 1515-1519
36. Eickhoff P., Valipour A., Kiss D., Schreder M., Cekici L., Geyer K., Kohansai R., and Burghuber O.C. Determinants of systemic vascular function in patients with stable chronic obstructive pulmonary disease. Am J Respir Cit Care Med 178 (2008) 1211-1218
37. Sikkel M.B., Quint J.K., Mallia P., Wedzicha J.A., and Johnston S.L. Respiratory syncytial virus persistence in chronic obstructive pulmonary disease. Pediatr Infect Dis J 27 (2008) S63-S70. Review article bringing together evidence that RSV is involved in COPD exacerbation.
38. Dicpinigaitis P.V., Spinner L., Santhyadka G., and Negassa A. Effect of tiotropium on cough reflex sensitivity in acute viral cough. Lung 186 (2008) 369-374
39. Iesato K., Tatsumi K., Saito K., Ogasawara T., Sakao S., Tada Y., Kasahara Y., Kurosu K., Tanabe N., Takiguchi Y., et al. Tiotropium bromide attenuates respiratory syncytial virus replication in epithelial cells. Respiration 76 (2008) 434-441. Paper demonstrating that tiotropium inhibited RSV replication in epithelium and the ensuing inflammatory response.
40. Undem B., and Pollack M. The role of vagal afferent nerves in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2 (2005) 355-360
41. Fryer A.D., and Jacoby D.D. Muscarinic receptors and the control of airway smooth muscle. Am J Respir Crit Care Med 158 (1998) S154-S160
42. On L.S., Boonyongsunchai P., Webb S., Davies L., Calverley P.M.A., and Costello R.W. Function of pulmonary neuronal M2 muscarinic receptors in stable chronic pulmonary disease. Am J Respir Crit Care Med 163 (2001) 1320-1325